Ehrlichiosis

Table of Contents

1. Overview
2. Epidemiology
3. Pathophysiology
4. Etiology and Risk Factors
5. Clinical Presentation
6. Diagnosis
7. Treatment
8. Complications
9. Prognosis
10. Prevention
11. References
12. Research Papers
13. Connections
14. Featured Videos

1. Overview

Ehrlichiosis is a collective term for two clinically similar but etiologically distinct tick-borne infections caused by obligate intracellular gram-negative bacteria of the family Anaplasmataceae. Human Monocytic Ehrlichiosis (HME) is caused by Ehrlichia chaffeensis, transmitted primarily by the Lone Star tick (Amblyomma americanum) across the Southeast and South-Central United States. Human Granulocytic Anaplasmosis (HGA) — formerly called Human Granulocytic Ehrlichiosis (HGE) before reclassification — is caused by Anaplasma phagocytophilum, transmitted by the black-legged tick (Ixodes scapularis) in the Northeast and Upper Midwest, and the western black-legged tick (Ixodes pacificus) on the Pacific Coast.

These organisms were not recognized as human pathogens until the late 1980s and early 1990s. E. chaffeensis was first described from a human case in 1987; A. phagocytophilum was identified as a human pathogen in 1994. Despite their relatively recent discovery, both are nationally reportable diseases with thousands of cases annually in the United States, and both can cause life-threatening illness if treatment is delayed.

The clinical importance of ehrlichiosis and anaplasmosis lies in their shared classic presentation — fever, headache, and myalgia following tick exposure — combined with distinctive laboratory abnormalities (leukopenia with lymphopenia, thrombocytopenia, and transaminitis) that, when recognized, point directly to the diagnosis and the singular effective treatment: doxycycline. Prompt empiric treatment before laboratory confirmation is essential and markedly reduces mortality.

Back to Table of Contents

2. Epidemiology

Human Monocytic Ehrlichiosis (HME): Approximately 2,000–3,000 cases are reported to the CDC annually. Geographic distribution follows the range of Amblyomma americanum: highest incidence in Arkansas, Missouri, Oklahoma, Tennessee, Virginia, North Carolina, and other Southeast and South-Central states. Cases occur primarily from April through September, peaking in June–July. Deer serve as the primary vertebrate reservoir for E. chaffeensis, which explains the strong association with deer-hunting and wooded rural environments. White-tailed deer maintain persistent, high-level bacteremia that supports tick acquisition without apparent clinical disease.

Human Granulocytic Anaplasmosis (HGA): Approximately 5,000–7,000 cases reported annually (making it the most common tick-borne disease in the US after Lyme disease in some years). Concentrated in the Northeast (New York, New Jersey, Connecticut, Massachusetts, Pennsylvania) and Upper Midwest (Wisconsin, Minnesota) — mirroring the Lyme disease belt. The same tick (I. scapularis) and the same reservoir (white-footed mouse, Peromyscus leucopus) are shared with B. burgdorferi (Lyme) and Babesia microti, explaining the geographic overlap and possibility of co-infection. I. pacificus on the West Coast accounts for a smaller proportion of cases.

Co-infection: In areas where I. scapularis ticks are endemic, studies have found that up to 10–20% of Lyme disease patients are co-infected with A. phagocytophilum, and a similar proportion may harbor Babesia microti. Co-infected patients tend to have more prolonged and severe illness than those with a single infection.

Underreporting: Surveillance data significantly underestimate true incidence. Many cases are mild and never reach medical attention; of those that do, many are not serologically confirmed or reported. Seroprevalence studies in endemic areas suggest 10–30 times more infections than reported cases.

Back to Table of Contents

3. Pathophysiology

Both E. chaffeensis and A. phagocytophilum are obligate intracellular pathogens that survive and replicate within membrane-bound vacuoles inside specific circulating leukocytes:

• Ehrlichia chaffeensis (HME): Infects monocytes and macrophages. After receptor-mediated endocytosis, the organism resides in early endosome-derived vacuoles and prevents lysosomal fusion, subverting phagosome maturation via type IV secretion system effectors. This allows intracellular replication to proceed within what appears to be a modified early endosome.
• Anaplasma phagocytophilum (HGA): Infects neutrophils (polymorphonuclear leukocytes). Remarkably, it exploits the cell type whose primary function is to kill intracellular pathogens. It achieves this by inhibiting NADPH oxidase-dependent killing, suppressing neutrophil apoptosis, and modulating cytokine responses to delay innate immune clearance.

Morulae: The characteristic intracytoplasmic inclusions — clusters of replicating organisms within a vacuole — are called morulae (Latin for "mulberry," from their clustered appearance). In HGA, morulae are visible in neutrophils on peripheral blood smear in 20–80% of cases, making smear examination a valuable rapid diagnostic tool. In HME, morulae are seen in monocytes in fewer than 20% of cases, limiting smear sensitivity.

Leukopenia and thrombocytopenia are pathognomonic laboratory findings. The mechanisms are multifactorial: direct infection and destruction of leukocytes, bone marrow suppression from cytokine release (TNF-α, IFN-γ, IL-1β), splenic sequestration, and complement-mediated clearance. Elevated transaminases reflect hepatic involvement — both direct hepatocyte infection and immune-mediated hepatitis. The systemic inflammatory response, rather than direct tissue invasion, accounts for most organ damage.

Back to Table of Contents

4. Etiology and Risk Factors

HME: Ehrlichia chaffeensis is transmitted exclusively by Amblyomma americanum (Lone Star tick) in the US. The tick is named for the single silver spot on the adult female's back. All three active stages (larva, nymph, adult) can feed on humans; adults are the most commonly implicated in transmission. White-tailed deer are the primary reservoir. The tick's host range is broad — it also feeds on dogs, raccoons, and other wildlife. Tick attachment of at least 24 hours is generally required for transmission.

HGA: Anaplasma phagocytophilum is transmitted by Ixodes scapularis in the Northeast and Midwest, and Ixodes pacificus on the Pacific Coast. Transmission requires tick attachment of 24–36 hours. The same tick transmits Borrelia burgdorferi (Lyme) and Babesia microti, making co-infection a realistic consideration in any patient presenting with tick-borne illness in endemic areas.

Risk factors for acquiring ehrlichiosis or anaplasmosis:

• Residence in or travel to endemic areas during tick season (May–September).
• Outdoor activities: hiking, camping, gardening, hunting, or working in wooded or brushy areas.
• Occupational exposure: forestry workers, military personnel, agricultural workers, wildlife managers.
• Owning a dog — dogs are frequently infested with Amblyomma or Ixodes ticks and may bring ticks indoors.

Risk factors for severe disease:

• Immunosuppression: HIV/AIDS, organ transplantation, corticosteroid therapy, chemotherapy, biologic agents.
• Age >60 years — elderly patients have higher rates of hospitalization and complications.
• Delayed diagnosis and treatment — the single most modifiable risk factor for fatal outcome.
• Diabetes mellitus and chronic organ disease may contribute to severe presentations.

Back to Table of Contents

5. Clinical Presentation

The incubation period for both HME and HGA is 5–14 days after tick bite, though a history of a recognized tick bite is elicited in only 60–80% of confirmed cases — nymphal-stage ticks are small enough to go unnoticed.

Classic triad (shared by both HME and HGA):

• Fever — abrupt onset, typically 38.5–40°C, often high-grade and sustained.
• Headache — often severe, frontal or diffuse.
• Myalgia — diffuse muscle aches, often prominent.

Additional symptoms include malaise, chills, nausea, vomiting, and anorexia. Arthralgias are less prominent than in Lyme disease. The illness resembles a severe viral syndrome.

Rash: This is the most clinically important distinction between HME, HGA, and Rocky Mountain Spotted Fever.

• HME (E. chaffeensis): Rash present in approximately 30% of adults and up to 60% of children; macular, maculopapular, or petechial; appears after fever onset (days 5–7). May involve palms and soles (less reliably than RMSF).
• HGA (A. phagocytophilum): Rash is distinctly rare — present in fewer than 10% of cases. Its absence should not be taken as reassurance in a febrile tick-exposed patient with leukopenia and thrombocytopenia.

Key laboratory findings (hallmark of both diseases):

• Leukopenia (WBC typically 2,000–4,000/μL), particularly lymphopenia early and neutropenia in HGA.
• Thrombocytopenia (platelets typically 50,000–100,000/μL).
• Elevated AST and ALT (transaminitis), often 2–5× the upper limit of normal.
• Mildly elevated creatinine; hyponatremia in severe cases; anemia in prolonged illness.
• These three laboratory abnormalities in combination with fever and tick exposure history in an endemic area should trigger empiric doxycycline therapy without awaiting confirmatory testing.

Clinical severity: Most patients recover with prompt antibiotic therapy. However, 40–60% of untreated or delayed-treated patients with HME require hospitalization; case fatality rates of 1–3% for HME and 0.5–1% for HGA with appropriate treatment; much higher with delayed or absent treatment, particularly in immunocompromised individuals.

Back to Table of Contents

6. Diagnosis

Ehrlichiosis and anaplasmosis are clinical diagnoses requiring empiric treatment before laboratory confirmation. The CDC case definition supports diagnosis on clinical + epidemiologic grounds (fever in a tick-endemic area + leukopenia/thrombocytopenia/transaminitis) while confirmatory testing is pending.

PCR (blood, whole blood in EDTA tube): Most sensitive test during acute febrile illness, before antibiotic therapy. Real-time PCR targeting species-specific sequences can distinguish E. chaffeensis (HME) from A. phagocytophilum (HGA). Sensitivity is approximately 60–85% for HME and 67–90% for HGA in the early acute phase; sensitivity drops sharply after antibiotic initiation. PCR should be ordered as part of the initial workup but treatment must not wait for results.

Peripheral blood smear (buffy coat preparation):

• HGA: Morulae visible in neutrophils in 20–80% of cases (higher sensitivity in early disease and high bacteremia); a positive smear provides rapid confirmation within hours.
• HME: Morulae visible in monocytes in fewer than 20% of cases — low sensitivity limits clinical utility, but a positive smear is confirmatory.
• Buffy coat preparation (concentration of leukocytes) improves sensitivity over routine peripheral smear.

Serology (indirect immunofluorescence antibody, IFA): A 4-fold rise in IgG titer between acute and convalescent specimens (collected 4–6 weeks apart) is diagnostic. Acute-phase serology is often negative (antibodies develop 7–14 days into illness) and should not be used to exclude the diagnosis. Single acute-phase IgG ≥1:64 for A. phagocytophilum or ≥1:128 for E. chaffeensis is suggestive but not confirmatory on its own.

CBC and chemistry panel: Leukopenia + thrombocytopenia + transaminitis in a febrile patient with tick exposure is the critical diagnostic triad. These routine laboratory findings are often available within hours and should prompt immediate doxycycline therapy when the clinical picture fits. Absence of these findings makes ehrlichiosis/anaplasmosis less likely.

Testing for co-infections: In patients from areas where I. scapularis is endemic, order simultaneous Lyme serology and Babesia smear/PCR. Patients with persistent or worsening illness despite doxycycline therapy should be evaluated for babesiosis co-infection (which does not respond to doxycycline).

Back to Table of Contents

7. Treatment

Doxycycline is the treatment of choice for all ages, including children and pregnant women in whom the benefits outweigh risks. This is an important point: concerns about tooth discoloration from tetracyclines in children under 8 years of age, or about fetal effects in pregnancy, should not delay or prevent doxycycline use in confirmed or suspected ehrlichiosis/anaplasmosis, as untreated disease can be fatal.

Adults and Children Over 45 kg

• Doxycycline 100 mg PO or IV twice daily × 5–10 days (at least 3 days after defervescence). Most patients defervesce within 24–48 hours of starting doxycycline; failure to improve within 48–72 hours should raise concern for an alternative diagnosis, drug-resistant organism, or co-infection.
• The recommended minimum course is 5–7 days for uncomplicated disease; 10–14 days for patients with CNS involvement or severe illness.

Children Under 45 kg

• Doxycycline 2.2 mg/kg PO or IV twice daily (max 100 mg per dose) × 5–10 days. The American Academy of Pediatrics endorses doxycycline for tick-borne diseases in all pediatric age groups including children under 8 years when the indication is clear — the short course used for tick-borne illness does not cause clinically significant tooth staining.

Pregnancy

• Doxycycline is the preferred agent for severe or confirmed ehrlichiosis/anaplasmosis in pregnancy. Untreated ehrlichiosis in pregnancy has caused fetal death and maternal death — the risk of the disease outweighs the theoretical teratogenicity concern for a short treatment course.
• Rifampin 300 mg PO twice daily × 5–7 days is an alternative for HGA in mild disease in pregnancy if doxycycline is truly contraindicated — but rifampin is NOT effective against HME.

Doxycycline-Allergic Patients

• Rifampin has demonstrated activity against A. phagocytophilum (HGA) only; it is not effective for E. chaffeensis (HME).
• Chloramphenicol is an alternative for HME in severely doxycycline-intolerant patients but has serious toxicity and is not preferred.
• If true doxycycline allergy: consult infectious disease specialists promptly. The safest approach in severe disease is often doxycycline desensitization.

Back to Table of Contents

8. Complications

• Meningoencephalitis: Occurs in up to 20% of severe HME cases; less common in HGA. Presents as confusion, altered mental status, meningism, or focal neurological deficits. CSF pleocytosis is typically lymphocytic. Untreated neurologic ehrlichiosis has high mortality and residual neurologic deficits.
• Acute respiratory distress syndrome (ARDS): Non-cardiogenic pulmonary edema from cytokine-driven capillary injury; may require mechanical ventilation.
• Multiorgan failure: Hepatic failure (rare, severe transaminitis in HME), renal failure (acute tubular necrosis), and cardiovascular collapse in fulminant cases.
• Disseminated intravascular coagulation (DIC): Particularly in severe HME; thrombocytopenia from ehrlichiosis may be severe enough to cause bleeding.
• Opportunistic infections: The pronounced leukopenia and immune suppression from severe ehrlichiosis can facilitate secondary fungal (candidiasis, cryptococcosis) or viral (CMV) infections in immunocompromised hosts.
• Death: Case fatality rates of 1–3% for HME and 0.5–1% for HGA overall; up to 10% in immunocompromised patients and those with delayed diagnosis. The majority of deaths are preventable with early doxycycline therapy.
• Prolonged fatigue and cognitive effects: Some patients report persistent fatigue and neurocognitive symptoms for weeks to months after acute illness, similar to post-Lyme disease syndrome. The mechanism is not fully understood.

Back to Table of Contents

9. Prognosis

With prompt doxycycline treatment: Prognosis is excellent. Fever typically resolves within 24–48 hours. Most patients recover fully within 1–2 weeks. Severe complications are uncommon when treatment begins within the first 5 days of illness.

Without treatment or with delayed treatment: Both HME and HGA can progress rapidly to life-threatening multiorgan failure. The case fatality rate rises substantially with each day of treatment delay. Immunocompromised patients are at highest risk for fatal outcomes, with reported mortality rates of 10% or higher in this group.

Predictors of poor outcome: Immunosuppression, age over 60, delayed diagnosis (>7 days from symptom onset to treatment), initial platelet count below 50,000/μL, involvement of the CNS, and the development of ARDS or multiorgan failure.

Relapse: Relapse is uncommon with an adequate treatment course (minimum 5–7 days or 3 days after defervescence). Shortened or sub-therapeutic courses are associated with relapse, particularly in immunocompromised patients. Drug resistance to doxycycline has not been documented in clinical isolates.

Back to Table of Contents

10. Prevention

There is no licensed vaccine against either Ehrlichia chaffeensis or Anaplasma phagocytophilum for human use. Prevention rests entirely on avoiding tick bites and prompt tick removal.

Personal protection measures:

• Apply DEET (20–30%) to exposed skin; permethrin to clothing, boots, and gear (not skin). Permethrin-treated clothing retains acaricidal activity through multiple washings and is highly effective against nymphal Amblyomma and Ixodes ticks.
• Wear light-colored clothing with long sleeves and pants tucked into socks when in tick-endemic areas. Light colors make ticks easier to spot during tick checks.
• Conduct full-body tick checks within 2 hours of potential tick exposure. Pay particular attention to the scalp, behind the ears, the axillae, the groin, and behind the knees — preferred attachment sites for both Amblyomma and Ixodes.
• Shower promptly after outdoor activities in endemic areas.
• Remove attached ticks promptly with fine-tipped tweezers (grasp near the skin surface; pull upward with steady even pressure). Reducing tick attachment time below 24 hours largely prevents Ehrlichia and Anaplasma transmission.

Residential and environmental measures:

• Keep grass short and remove leaf litter from residential yards; create a wood-chip buffer zone between wooded areas and lawns.
• Treat dogs with veterinarian-approved tick preventatives; examine dogs after outdoor activities.
• Apply yard acaricides (bifenthrin, permethrin, or carbaryl) in endemic areas, particularly at wood-lawn interfaces.

Clinical awareness: Early diagnosis depends on clinicians recognizing the clinical syndrome and initiating empiric treatment promptly. Patients in endemic areas should be counseled to report febrile illnesses following any outdoor activity and to mention any history of tick attachment or exposure, however uncertain.

Back to Table of Contents

11. References

1. Paddock CD, Childs JE. Ehrlichia chaffeensis: a prototypical emerging pathogen. Clin Microbiol Rev. 2003;16:37–64. PMID: 12525424. https://doi.org/10.1128/CMR.16.1.37-64.2003
2. Dumler JS, Madigan JE, Pusterla N, Bakken JS. Ehrlichioses in humans: epidemiology, clinical presentation, diagnosis, and treatment. Clin Infect Dis. 2007;45 Suppl 1:S45–51. PMID: 17582569. https://doi.org/10.1086/518146
3. Bakken JS, Dumler JS. Human granulocytic anaplasmosis. Infect Dis Clin North Am. 2015;29:341–355. PMID: 25999228. https://doi.org/10.1016/j.idc.2015.02.007
4. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006;43:1089–1134. PMID: 17029130. https://doi.org/10.1086/508667
5. Thomas RJ, Dumler JS, Carlyon JA. Current management of human granulocytic anaplasmosis, human monocytic ehrlichiosis and Ehrlichia ewingii ehrlichiosis. Expert Rev Anti Infect Ther. 2009;7:709–722. PMID: 19681699. https://doi.org/10.1586/eri.09.44
6. Ismail N, Bloch KC, McBride JW. Human ehrlichiosis and anaplasmosis. Clin Lab Med. 2010;30:261–292. PMID: 20513553. https://doi.org/10.1016/j.cll.2010.01.002
7. Olano JP, Walker DH. Human ehrlichioses. Med Clin North Am. 2002;86:375–392. PMID: 11982308. https://doi.org/10.1016/s0025-7125(03)00090-3
8. Sanchez E, Vannier E, Wormser GP, Hu LT. Diagnosis, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: a review. JAMA. 2016;315:1767–1777. PMID: 27115378. https://doi.org/10.1001/jama.2016.2884
9. Bakken JS, Dumler S. Clinical diagnosis and treatment of human granulocytotropic anaplasmosis. Ann N Y Acad Sci. 2006;1078:236–247. PMID: 17114714. https://doi.org/10.1196/annals.1374.042
10. Tickborne Diseases of the United States: A Reference Manual for Health Care Providers. Centers for Disease Control and Prevention. 2017. https://www.cdc.gov/lyme/resources/TickborneDiseases.pdf
11. Massung RF, Slater KG. Comparison of PCR assays for detection of the agent of human granulocytic ehrlichiosis, Anaplasma phagocytophilum. J Clin Microbiol. 2003;41:717–722. PMID: 12574272. https://doi.org/10.1128/JCM.41.2.717-722.2003
12. Srikantiah P, Rollin PE, Albarino CG, et al. Human ehrlichiosis — an underappreciated risk for travelers. J Travel Med. 2002;9:143–146. PMID: 12044285. https://doi.org/10.2310/7060.2002.23682

Back to Table of Contents

Research Papers

The following PubMed topic searches retrieve current peer-reviewed literature on Ehrlichiosis and Anaplasmosis.

1. Ehrlichiosis Ehrlichia chaffeensis treatment
2. Anaplasma phagocytophilum anaplasmosis
3. Ehrlichiosis doxycycline tick-borne
4. Morulae Ehrlichia blood smear diagnosis
5. Human granulocytic anaplasmosis Lyme co-infection
6. Ehrlichiosis leukopenia thrombocytopenia transaminitis
7. Amblyomma americanum Lone Star tick Ehrlichia
8. Anaplasma phagocytophilum intracellular pathogenesis
9. Ehrlichiosis children pediatric doxycycline
10. Ehrlichiosis immunocompromised complications
11. Tick-borne disease prevention DEET permethrin
12. Ehrlichiosis meningoencephalitis neurologic

Back to Table of Contents

Connections

• Lyme Disease
• Babesiosis
• Rocky Mountain Spotted Fever
• Q Fever
• Brucellosis
• Infectious Disease
• Meningitis
• Thrombocytopenia
• Complete Blood Count
• Pneumonia
• Immune Boosting
• Andrographis

Back to Table of Contents

Featured Videos